

ZOGENIX

Zogenix to Present at Stifel Nicolaus 2012 Healthcare Conference

August 30, 2012

SAN DIEGO, Aug. 30, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, today announced that Roger L. Hawley, Chief Executive Officer, and Ann Rhoads, Executive Vice President and Chief Financial Officer, will be presenting at the Stifel Nicolaus 2012 Healthcare Conference on September 6, 2012 in Boston, MA.

Event: Stifel Nicolaus 2012 Healthcare Conference

Date: Thursday, September 6, 2012

Place: Boston, MA

Time: 10:55 am ET

The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com. Mr. Hawley and Ms. Rhoads will also be available to participate in one-on-one meetings at the conference.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL[®] DosePro[®] (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro[™] ER (hydrocodone bitartrate) is an oral, single-entity (without acetaminophen) novel extended-release formulation of various strengths of hydrocodone intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, Relday[™], is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL[®], DosePro[®], Relday[™] and Zohydro[™] ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:

Zack Kubow | The Ruth Group
646.536.7020 | zkubow@theruthgroup.com

MEDIA:

Victoria Aguiar | The Ruth Group
646.536.7013 | vaguiar@theruthgroup.com

Zogenix